ClinicalTrials.Veeva

Menu
D

Dawes Fretzin Clinical Research Group | Indianapolis, IN

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PF-04965842
Ruxolitinib
Apremilast
Guselkumab
JNJ-77242113
Dupilumab
Rocatinlimab
Baricitinib
ASN002
LY3009104

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

38 of 140 total trials
Locations recently updated

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-61...

Enrolling
Non-segmental Vitiligo
Biological: MK-6194
Drug: Placebo

This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD....

Active, not recruiting
Atopic Dermatitis
Drug: Difamilast

This is a parallel, Phase 2, 2-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult par...

Enrolling
Hidradenitis Suppurativa
Drug: SAR444656 (KT-474)
Drug: Placebo
Locations recently updated

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The coprimary objectives of the study are to:* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcin...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab
Locations recently updated

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 1...

Enrolling
Plaque Psoriasis
Drug: Apremilast
Locations recently updated

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: JNJ-77242113

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and ge...

Enrolling
Palmoplantar Psoriasis
Genital Psoriasis
Drug: Placebo
Drug: Deucravacitinib

This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It is designed to assess th...

Enrolling
Psoriasis
Drug: SAR441566
Drug: Placebo

Trial sponsors

Pfizer logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Boehringer Ingelheim logo
Incyte logo
Sanofi logo
Galderma logo
LEO Pharma logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems